Vericel (NASDAQ:VCEL) Stock Crosses Above Two Hundred Day Moving Average – What’s Next?

Vericel Co. (NASDAQ:VCEL)’s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $49.27 and traded as high as $59.43. Vericel shares last traded at $58.08, with a volume of 394,963 shares changing hands.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Truist Financial upped their target price on shares of Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Stephens raised Vericel to a “strong-buy” rating in a research report on Monday, December 2nd. Canaccord Genuity Group reiterated a “buy” rating and issued a $60.00 target price on shares of Vericel in a report on Tuesday, November 19th. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, December 24th. Finally, BTIG Research lifted their price objective on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $61.14.

Vericel Price Performance

The company has a 50 day moving average price of $55.40 and a 200 day moving average price of $49.43. The firm has a market cap of $2.94 billion, a PE ratio of 992.33 and a beta of 1.72.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.03. The company had revenue of $57.91 million during the quarter, compared to analysts’ expectations of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. On average, equities analysts anticipate that Vericel Co. will post 0.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Jonathan Mark Hopper sold 10,000 shares of Vericel stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $58.72, for a total transaction of $587,200.00. Following the completion of the transaction, the insider now directly owns 58,371 shares of the company’s stock, valued at approximately $3,427,545.12. The trade was a 14.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Steven C. Gilman sold 5,833 shares of Vericel stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $41.36, for a total transaction of $241,252.88. Following the transaction, the director now owns 11,000 shares of the company’s stock, valued at approximately $454,960. The trade was a 34.65 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,433 shares of company stock worth $1,855,275. 5.20% of the stock is owned by corporate insiders.

Institutional Trading of Vericel

Several institutional investors and hedge funds have recently made changes to their positions in VCEL. International Assets Investment Management LLC raised its stake in Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 619 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 405 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 322 shares during the period. Meeder Asset Management Inc. purchased a new stake in Vericel in the 3rd quarter worth approximately $92,000. Finally, Quantbot Technologies LP acquired a new position in Vericel in the 3rd quarter valued at $146,000.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.